MC-GGFG-DX8951 is a DX8951 derivative with MC-GGFG linker, in which DX8951 was covalently connected via a peptidyl spacer (Gly-Gly-Phe-Gly), which is assumed to be stable in circulation, and were cleaved by lysosomal enzymes following ADC internalization into tumor tissue. MC-GGFG-DX8951 is very useful to prepare DX8951 antibody conjugate (ADC).
Catalog Number | Size | Price | Quantity | |
---|---|---|---|---|
BADC-00608 | -- | $-- | Inquiry |
MC-GGFG-DX8951 represents a novel advancement in the field of targeted cancer therapeutics, serving as a pivotal compound for the development of DX8951-based antibody-drug conjugates (ADCs). These conjugates are designed to selectively deliver the potent anticancer agent DX8951 directly to tumor cells. The use of a peptidyl spacer, specifically Gly-Gly-Phe-Gly, connects DX8951 covalently, ensuring that the drug remains stable during circulation, significantly reducing systemic toxicity. This stability is crucial for minimizing side-effects often associated with chemotherapy and improving patient quality of life
The mechanism of action for MC-GGFG-DX8951 begins with its incorporation into an ADC, which involves linking the drug to a monoclonal antibody that specifically targets antigens expressed on cancer cells. Once the ADC binds to the tumor cell surface, it undergoes internalization primarily through receptor-mediated endocytosis. Inside the tumor cells, the MC-GGFG linker is cleaved by lysosomal enzymes. This enzymatic cleavage is a critical step, releasing DX8951 in its active form directly within the lysosome, thereby achieving a more effective and targeted cytotoxic effect. This approach not only enhances the drug concentration at the tumor site but also mitigates adverse effects on healthy tissues
MC-GGFG-DX8951 is particularly valuable in the context of solid tumors where conventional therapies have limited efficacy. Its application in ADC technology allows for the personalization of cancer treatment, enabling therapies to be tailored based on the specific molecular profiles of tumors. This approach can lead to improved response rates and outcomes in patients who are resistant to standard chemotherapeutic agents. Furthermore, by leveraging the antigen-specific targeting capabilities of monoclonal antibodies, MC-GGFG-DX8951-based ADCs exhibit a higher specificity, reducing off-target effects and enhancing the therapeutic index
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.